Pioneering Ultra-Diverse DNA Libraries for AI-Driven Biotech

Gnome Biotechnologies leads the charge in synthesizing ultra-diverse DNA libraries exceeding 10¹⁵ variants, powering high-throughput screening and AI model training for antibody discovery, gene therapy, and bioenergy.

Learn More

Technology

Transforming Protein Engineering with DNA Synthesis

Building the future of biotech with unmatched library diversity and high-throughput screening to unlock novel proteins and train advanced AI models.

Unprecedented Library Diversity

Synthesize DNA libraries exceeding 10¹⁵ variants, enabling exhaustive exploration of human antibody repertoires and beyond for AI-driven discovery.

Long-Fragment Synthesis

Produce longer, high-fidelity DNA fragments with >95% accuracy, supporting complex antibody structures and enzyme designs without sequence errors.

Massively Parallel Screening

Enable high-throughput screening at scale, generating vast datasets to train AI models and identify rare, high-value antibodies and enzymes.

About Us

Leading the Biotech Revolution with Ultra-Diverse Libraries

Founded in 2025, Gnome Biotechnologies is redefining synthetic biology by producing ultra-diverse DNA libraries (10¹⁵+ variants) and enabling massively parallel high-throughput screening. Our mission is to generate the vast sequence data needed to train AI models, unlocking breakthroughs in antibody discovery, gene therapy, and bioenergy.

Our platform overcomes bottlenecks in traditional DNA synthesis, delivering longer fragments and unparalleled diversity to explore sequence spaces for novel proteins and sustainable solutions. Join us in building the biotech infrastructure of the future.

FAQ

Common Questions

Insights into our DNA synthesis and high-throughput screening platform.

Our platform delivers ultra-diverse libraries (10¹⁵+ variants) with long, high-fidelity fragments, enabling massively parallel screening to generate AI-training data and identify rare antibodies and enzymes.

Provisional patent filed in 2025; converting to non-provisional in Q1 2026 for full protection.

Antibody discovery, gene therapy vectors, protein therapeutics, and bioenergy enzyme optimization, powered by vast sequence data for AI models.

Collaborating with academic labs, pharma, and biotech leaders for validation and scaling; open to strategic alliances to advance biotech infrastructure.

Our Team

Meet The Founders

Experts in synthetic biology and AI-driven biotech shaping the future of protein engineering.

John Poncini

CEO & Founder

Ready to Shape the Future of Biotech?

Our Location

Santa Cruz, CA, USA

Get In Touch

info@gnomebiotech.com

partnerships@gnomebiotech.com